We recently published 10 Stocks Crushing Wall Street, AI Stocks Dominate. Uniqure NV (NASDAQ:QURE) is one of the top performers on Tuesday. Shares of Uniqure NV soared by as much as 275 percent on Wednesday to hit a new all-time high as investors cheered stellar results from the clinical trial of its drug candidate for Huntington’s disease. During the session, shares of the company soared to its highest price of $51.21 before trimming gains to end the day just up by 247.73 percent at $47.50 apiece. Uniq ...

Key Takeaways Viking is advancing VK2735 in oral and subcutaneous forms to treat obesity.Pfizer's $4.9B Metsera buy will add four obesity drug programs to its pipeline.Mixed trial results for VKTX's oral VK2735 shift focus to the injectable version.Viking Therapeutics (VKTX) remains one of the few clinical-stage biotechs making meaningful progress in obesity drug development. The company is developing VK2735, an investigational novel dual GLP-1 and GIP receptor agonist (RA), in multiple clinical studies as ...

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P 1500 Health Care Index declined 6.9% in the second quarter, underperforming the S&P 500’s 10.9% return. Health care providers & services, life science ...

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P 1500 Health Care Index declined 6.9% in the second quarter, underperforming the S&P 500’s 10.9% return. Health care providers & services, life science ...

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant volatility, as the steep sell-off that initiated at the beginning of the quarter ultimately led to a strong recovery. The S&P 1500 Health Care Index declined 6.9% in the second quarter, underperforming the S&P 500’s 10.9% return. Health care providers & services, life science ...

One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical measures observed at 24 monthsContinue to observe generally favorable safety data with no new drug-related events within the follow-up periodData presented today at the 5th International ATTR Amyloidosis Annual Meeting for Patients and Doctors with simultaneous publication in the New England Journal of Medici ...

PepGen Inc. (NASDAQ: PEPG) stock is skyrocketing on Thursday, with a session volume of 53.04 million compared to the average volume of 943.2 thousand as per data from Benzinga Pro.PepGen on Wednesday released clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study in patients with myotonic dystrophy type 1 (DM1).Myotonic dystrophy is a rare, inherited genetic disorder characterized by progressive muscle weakness and myotonia, which is the inabil ...

It’s a sign that’s impossible to ignore. As you soon as you pull up the Price Overview for Recursion Pharmaceuticals (RXRX), you’re greeted with a clear message: Barchart’s Technical Opinion indicator rates RXRX stock as a 72% Strong Sell. From an empirical perspective, suggesting a contrarian position would place you on shaky ground. Since the start of the year, RXRX stock is down nearly 28%, which in many respects is understandable given the uncertainties associated with the broader healthcare ecosystem ...

Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Capital MarketGRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced that it has received written notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming that th ...

https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=168877&from=4 CLASS PERIOD: March 4, 2024 to May 23, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MO ...